Clinical trials
Leukemia, Myeloid, Acute trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2016 | 5 |
| 2017 | 7 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 6 |
| Terminated | 6 |
| Active, not recruiting | 4 |
| Unknown status | 4 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 3 |
| Daiichi Sankyo | 3 |
| Hospital Israelita Albert Einstein | 2 |
| Hospital de Clinicas de Porto Alegre | 2 |
| Novartis Pharmaceuticals | 2 |
| Astellas Pharma Global Development, Inc. | 1 |
| Astellas Pharma Singapore Pte. Ltd. | 1 |
| Boehringer Ingelheim | 1 |
| Celgene | 1 |
| Gamida Cell ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 34 |
| Myelodysplastic Syndromes | 7 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Leukemia | 6 |
| Leukemia, Myelomonocytic, Chronic | 3 |
| Myeloproliferative Disorders | 3 |
| Graft vs Host Disease | 2 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 |
| Anemia, Refractory, with Excess of Blasts | 1 |
| Burkitt Lymphoma | 1 |
Trials
Showing 26 to 34 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.